The effectiveness of individual schema therapy in older adults with borderline personality disorder

Protocol of a multiple-baseline study

D. Khasho*, B. van Alphen, S.M.J. Heijnen-kohl, M.A. Ouwens, A. Arntz, A.C. Videler

*Corresponding author for this work

Research output: Contribution to journalArticleScientificpeer-review

4 Downloads (Pure)

Abstract

Background
The treatment of borderline personality disorder (BPD) has been examined extensively in adults up to the age of fifty in the past quarter of a century, but there is still a world to discover in treating BPD in older adults. The aim of the study is to investigate the effectiveness of schema therapy in older adults with BPD.
Methods/design
A multiple baseline design is used in which participants are randomly assigned to baseline length. The primary outcome measure is assessed weekly and consists of the credibility of negative core beliefs. Secondary outcome measures are quality of life, psychological distress, early maladaptive schemas, schema modes, severity of BPD symptoms and meeting the criteria for BPD. Ten older adults (age > 60 years) with BPD are treated with schema therapy, with weekly sessions during one year. This treatment phase is preceded by a baseline phase varying from 4 to 8 weeks. After treatment, there is a 6-month follow-up phase with monthly booster sessions.
Discussion
To our knowledge, this is the first empirical study of the effectiveness of psychotherapeutic treatment for BPD in older adults. Because of the different manifestation of BPD in later life, besides section II DSM-5 criteria, the alternative, dimensional model for personality disorders of DSM-5 is used to assess BPD in older adults.
Original languageEnglish
Article number100330
Number of pages5
JournalContemporary Clinical Trials Communications
Volume14
DOIs
Publication statusPublished - 2019

Keywords

  • AXIS II
  • Borderline personality disorder
  • COMMUNITY SAMPLE
  • CONSTRUCT-VALIDITY
  • INTERVIEW
  • INVENTORY
  • Multiple baseline case series
  • Older adults
  • Personality disorder
  • QUALITY-OF-LIFE
  • RANDOMIZATION TESTS
  • RELIABILITY
  • SEVERITY INDEXES
  • SYMPTOMS
  • Schema therapy

Cite this

@article{9e138602455a49359202b81b90abf022,
title = "The effectiveness of individual schema therapy in older adults with borderline personality disorder: Protocol of a multiple-baseline study",
abstract = "BackgroundThe treatment of borderline personality disorder (BPD) has been examined extensively in adults up to the age of fifty in the past quarter of a century, but there is still a world to discover in treating BPD in older adults. The aim of the study is to investigate the effectiveness of schema therapy in older adults with BPD.Methods/designA multiple baseline design is used in which participants are randomly assigned to baseline length. The primary outcome measure is assessed weekly and consists of the credibility of negative core beliefs. Secondary outcome measures are quality of life, psychological distress, early maladaptive schemas, schema modes, severity of BPD symptoms and meeting the criteria for BPD. Ten older adults (age > 60 years) with BPD are treated with schema therapy, with weekly sessions during one year. This treatment phase is preceded by a baseline phase varying from 4 to 8 weeks. After treatment, there is a 6-month follow-up phase with monthly booster sessions.DiscussionTo our knowledge, this is the first empirical study of the effectiveness of psychotherapeutic treatment for BPD in older adults. Because of the different manifestation of BPD in later life, besides section II DSM-5 criteria, the alternative, dimensional model for personality disorders of DSM-5 is used to assess BPD in older adults.",
keywords = "AXIS II, Borderline personality disorder, COMMUNITY SAMPLE, CONSTRUCT-VALIDITY, INTERVIEW, INVENTORY, Multiple baseline case series, Older adults, Personality disorder, QUALITY-OF-LIFE, RANDOMIZATION TESTS, RELIABILITY, SEVERITY INDEXES, SYMPTOMS, Schema therapy",
author = "D. Khasho and {van Alphen}, B. and S.M.J. Heijnen-kohl and M.A. Ouwens and A. Arntz and A.C. Videler",
year = "2019",
doi = "10.1016/j.conctc.2019.100330",
language = "English",
volume = "14",
journal = "Contemporary Clinical Trials Communications",
issn = "2451-8654",
publisher = "Elsevier Inc.",

}

The effectiveness of individual schema therapy in older adults with borderline personality disorder : Protocol of a multiple-baseline study. / Khasho, D.; van Alphen, B.; Heijnen-kohl, S.M.J.; Ouwens, M.A.; Arntz, A.; Videler, A.C.

In: Contemporary Clinical Trials Communications, Vol. 14, 100330, 2019.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - The effectiveness of individual schema therapy in older adults with borderline personality disorder

T2 - Protocol of a multiple-baseline study

AU - Khasho, D.

AU - van Alphen, B.

AU - Heijnen-kohl, S.M.J.

AU - Ouwens, M.A.

AU - Arntz, A.

AU - Videler, A.C.

PY - 2019

Y1 - 2019

N2 - BackgroundThe treatment of borderline personality disorder (BPD) has been examined extensively in adults up to the age of fifty in the past quarter of a century, but there is still a world to discover in treating BPD in older adults. The aim of the study is to investigate the effectiveness of schema therapy in older adults with BPD.Methods/designA multiple baseline design is used in which participants are randomly assigned to baseline length. The primary outcome measure is assessed weekly and consists of the credibility of negative core beliefs. Secondary outcome measures are quality of life, psychological distress, early maladaptive schemas, schema modes, severity of BPD symptoms and meeting the criteria for BPD. Ten older adults (age > 60 years) with BPD are treated with schema therapy, with weekly sessions during one year. This treatment phase is preceded by a baseline phase varying from 4 to 8 weeks. After treatment, there is a 6-month follow-up phase with monthly booster sessions.DiscussionTo our knowledge, this is the first empirical study of the effectiveness of psychotherapeutic treatment for BPD in older adults. Because of the different manifestation of BPD in later life, besides section II DSM-5 criteria, the alternative, dimensional model for personality disorders of DSM-5 is used to assess BPD in older adults.

AB - BackgroundThe treatment of borderline personality disorder (BPD) has been examined extensively in adults up to the age of fifty in the past quarter of a century, but there is still a world to discover in treating BPD in older adults. The aim of the study is to investigate the effectiveness of schema therapy in older adults with BPD.Methods/designA multiple baseline design is used in which participants are randomly assigned to baseline length. The primary outcome measure is assessed weekly and consists of the credibility of negative core beliefs. Secondary outcome measures are quality of life, psychological distress, early maladaptive schemas, schema modes, severity of BPD symptoms and meeting the criteria for BPD. Ten older adults (age > 60 years) with BPD are treated with schema therapy, with weekly sessions during one year. This treatment phase is preceded by a baseline phase varying from 4 to 8 weeks. After treatment, there is a 6-month follow-up phase with monthly booster sessions.DiscussionTo our knowledge, this is the first empirical study of the effectiveness of psychotherapeutic treatment for BPD in older adults. Because of the different manifestation of BPD in later life, besides section II DSM-5 criteria, the alternative, dimensional model for personality disorders of DSM-5 is used to assess BPD in older adults.

KW - AXIS II

KW - Borderline personality disorder

KW - COMMUNITY SAMPLE

KW - CONSTRUCT-VALIDITY

KW - INTERVIEW

KW - INVENTORY

KW - Multiple baseline case series

KW - Older adults

KW - Personality disorder

KW - QUALITY-OF-LIFE

KW - RANDOMIZATION TESTS

KW - RELIABILITY

KW - SEVERITY INDEXES

KW - SYMPTOMS

KW - Schema therapy

U2 - 10.1016/j.conctc.2019.100330

DO - 10.1016/j.conctc.2019.100330

M3 - Article

VL - 14

JO - Contemporary Clinical Trials Communications

JF - Contemporary Clinical Trials Communications

SN - 2451-8654

M1 - 100330

ER -